Pyrimidine compound as JAK kinase inhibitor
US11420965B2 · kind B2 · utility
2Cited by
16References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 30, 2021 |
| Grant date | Aug 23, 2022 |
| Priority date | — |
| Expiry date | Mar 30, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.